JP2015531749A - イトラコナゾール組成物及び投与剤形、並びにその使用方法 - Google Patents

イトラコナゾール組成物及び投与剤形、並びにその使用方法 Download PDF

Info

Publication number
JP2015531749A
JP2015531749A JP2015518624A JP2015518624A JP2015531749A JP 2015531749 A JP2015531749 A JP 2015531749A JP 2015518624 A JP2015518624 A JP 2015518624A JP 2015518624 A JP2015518624 A JP 2015518624A JP 2015531749 A JP2015531749 A JP 2015531749A
Authority
JP
Japan
Prior art keywords
oral pharmaceutical
pharmaceutical composition
composition
itraconazole
standard
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015518624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531749A5 (https=
Inventor
ジェイムズ マッジ，スチュアート
ジェイムズ マッジ，スチュアート
ヘイズ，デイヴィッド
ルーカス，ステファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayne Pharma International Pty Ltd
Original Assignee
Mayne Pharma International Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902624A external-priority patent/AU2012902624A0/en
Application filed by Mayne Pharma International Pty Ltd filed Critical Mayne Pharma International Pty Ltd
Publication of JP2015531749A publication Critical patent/JP2015531749A/ja
Publication of JP2015531749A5 publication Critical patent/JP2015531749A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015518624A 2012-06-21 2013-06-21 イトラコナゾール組成物及び投与剤形、並びにその使用方法 Pending JP2015531749A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902624 2012-06-21
AU2012902624A AU2012902624A0 (en) 2012-06-21 Itraconazole formulations and uses
PCT/US2013/047135 WO2013192566A1 (en) 2012-06-21 2013-06-21 Itraconazole compositions and dosage forms, and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018126027A Division JP6757367B2 (ja) 2012-06-21 2018-07-02 イトラコナゾール組成物及び投与剤形、並びにその使用方法

Publications (2)

Publication Number Publication Date
JP2015531749A true JP2015531749A (ja) 2015-11-05
JP2015531749A5 JP2015531749A5 (https=) 2016-08-12

Family

ID=49769445

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015518624A Pending JP2015531749A (ja) 2012-06-21 2013-06-21 イトラコナゾール組成物及び投与剤形、並びにその使用方法
JP2018126027A Active JP6757367B2 (ja) 2012-06-21 2018-07-02 イトラコナゾール組成物及び投与剤形、並びにその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018126027A Active JP6757367B2 (ja) 2012-06-21 2018-07-02 イトラコナゾール組成物及び投与剤形、並びにその使用方法

Country Status (11)

Country Link
US (7) US8921374B2 (https=)
EP (1) EP2863911A4 (https=)
JP (2) JP2015531749A (https=)
KR (3) KR20200065093A (https=)
CN (2) CN104507480A (https=)
AU (3) AU2013278001A1 (https=)
BR (1) BR112014031706A8 (https=)
CA (1) CA2876909C (https=)
HK (1) HK1207288A1 (https=)
MX (1) MX366829B (https=)
WO (1) WO2013192566A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014031706A8 (pt) 2012-06-21 2021-10-19 Mayne Pharma Int Pty Ltd Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
US11390613B2 (en) 2017-08-20 2022-07-19 University Of Connecticut Azole analogues and methods of use thereof
AU2019277362A1 (en) * 2018-05-30 2021-01-21 Mayne Pharma International Pty Ltd Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome
WO2021030174A1 (en) 2019-08-09 2021-02-18 University Of Connecticut Truncated itraconazole analogues and methods of use thereof
CN115768779A (zh) * 2020-05-07 2023-03-07 上海偕怡医药科技有限公司 伊曲康唑前药及其用途
WO2023007514A1 (en) * 2021-07-29 2023-02-02 Dr. Reddy's Laboratories Limited Improved oral bioavailable pharmaceutical compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518483A (ja) * 1999-12-23 2003-06-10 エフ エイチ フォールディング アンド カンパニー リミテッド 不良溶解性の薬物に対する改良された医薬組成物
JP2005504775A (ja) * 2001-08-27 2005-02-17 ウォン ジン バイオファーマ カンパニー リミテッド イトラコナゾールを含有する組成物及びその製造方法
WO2005023262A1 (en) * 2003-09-09 2005-03-17 Hanmi Pharm. Co., Ltd. Oral itraconazole composition which is not affected by ingested food and process for preparing same
JP2009504589A (ja) * 2005-08-08 2009-02-05 アボット ゲーエムベーハー ウント コンパニー カーゲー 改善された生物学的利用能をもつイトラコナゾール組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3110794B2 (ja) 1991-06-05 2000-11-20 ユーシービージャパン株式会社 １，４−ジヒドロピリジン誘導体を含有する製剤
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US6254889B1 (en) 1995-07-26 2001-07-03 Kyowa Hakko Kogyo Co., Ltd. Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer
ATE255883T1 (de) 1996-05-20 2003-12-15 Janssen Pharmaceutica Nv Fungizide mittel mit verbesserter bioverfügbarkeit
DE69730241T2 (de) 1996-06-28 2005-08-11 Schering Corp. Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
CA2317106C (en) 1997-12-31 2004-11-23 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
JP2002534371A (ja) 1999-01-06 2002-10-15 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
KR100529766B1 (ko) * 2003-09-09 2005-11-17 한미약품 주식회사 음식물 섭취에 따른 영향이 적은, 이트라코나졸경구투여용 조성물 및 이의 제조 방법
JP4342426B2 (ja) * 2004-11-24 2009-10-14 科研製薬株式会社 イトラコナゾール経口投与用製剤
WO2008002568A2 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
US20110262517A1 (en) * 2007-04-05 2011-10-27 The Johns Hopkins University Chirally pure isomers of itraconazole and inhibitors of lanosterol 14a-demethylase for use as angiogenesis inhibitors
BR112014031706A8 (pt) 2012-06-21 2021-10-19 Mayne Pharma Int Pty Ltd Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518483A (ja) * 1999-12-23 2003-06-10 エフ エイチ フォールディング アンド カンパニー リミテッド 不良溶解性の薬物に対する改良された医薬組成物
JP2005504775A (ja) * 2001-08-27 2005-02-17 ウォン ジン バイオファーマ カンパニー リミテッド イトラコナゾールを含有する組成物及びその製造方法
WO2005023262A1 (en) * 2003-09-09 2005-03-17 Hanmi Pharm. Co., Ltd. Oral itraconazole composition which is not affected by ingested food and process for preparing same
JP2009504589A (ja) * 2005-08-08 2009-02-05 アボット ゲーエムベーハー ウント コンパニー カーゲー 改善された生物学的利用能をもつイトラコナゾール組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 33, JPN6017017066, 2008, pages 159 - 165, ISSN: 0003557718 *

Also Published As

Publication number Publication date
US20140005205A1 (en) 2014-01-02
MX366829B (es) 2019-07-25
HK1207288A1 (en) 2016-01-29
US20160030582A1 (en) 2016-02-04
JP2018162304A (ja) 2018-10-18
CA2876909C (en) 2022-08-16
CN104507480A (zh) 2015-04-08
KR20200065093A (ko) 2020-06-08
EP2863911A1 (en) 2015-04-29
US10463740B2 (en) 2019-11-05
WO2013192566A1 (en) 2013-12-27
CA2876909A1 (en) 2013-12-27
US9272046B2 (en) 2016-03-01
JP6757367B2 (ja) 2020-09-16
AU2013278001A1 (en) 2015-01-22
US20190125879A1 (en) 2019-05-02
MX2015000179A (es) 2016-02-16
US20150099763A1 (en) 2015-04-09
US11638758B2 (en) 2023-05-02
KR20150043296A (ko) 2015-04-22
KR20210043721A (ko) 2021-04-21
US8921374B2 (en) 2014-12-30
US20210038728A1 (en) 2021-02-11
AU2018201298B2 (en) 2020-05-14
US20200138959A1 (en) 2020-05-07
EP2863911A4 (en) 2016-07-13
AU2018201298A1 (en) 2018-03-15
US9713642B2 (en) 2017-07-25
BR112014031706A8 (pt) 2021-10-19
AU2020217438A1 (en) 2020-09-03
US10806792B2 (en) 2020-10-20
US20170348421A1 (en) 2017-12-07
BR112014031706A2 (pt) 2017-06-27
CN109674795A (zh) 2019-04-26

Similar Documents

Publication Publication Date Title
JP6757367B2 (ja) イトラコナゾール組成物及び投与剤形、並びにその使用方法
TWI871342B (zh) 非鎮靜之右美托咪啶(dexmedetomidine)治療方案
AU2023233115A1 (en) Methods of treating eosinophilic esophagitis
US20110319384A1 (en) Pharmaceutical Compositions
CN102387802A (zh) 包含羟考酮和纳洛酮的立即释放药物组合物
JP7190425B2 (ja) 肝細胞癌の治療のための併用療法
WO2015089150A1 (en) Pharmaceutical formulations comprising vilazodone
IL269357B2 (en) A combination of ER? inhibitor and CDK 4/6 inhibitor for use in a method of treating breast cancer
Sakr et al. Pharmacokinetics of buspirone extended‐release tablets: a single‐dose study
US9913839B2 (en) Dosing regimens for fast onset of antidepressant effect
EP4601631A1 (en) Combination for use in treating cancers
US20250367137A1 (en) Phloroglucinol Formulations And Methods Of Use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180904